International Journal of Hematology

, 90:413

Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib

Authors

  • Ikumi Kasahara
    • Department of Medicine IIHokkaido University Graduate School of Medicine
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Satoshi Yamamoto
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Tomoyuki Endo
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Katsuya Fujimoto
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Keisuke Yamaguchi
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Yukari Takeda
    • Department of Medicine IIHokkaido University Graduate School of Medicine
    • Translational Research and Clinical Trial CenterHokkaido University Hospital
  • Hideki Goto
    • Department of Medicine IIHokkaido University Graduate School of Medicine
  • Norihiro Sato
    • Translational Research and Clinical Trial CenterHokkaido University Hospital
  • Takao Koike
    • Department of Medicine IIHokkaido University Graduate School of Medicine
Case Report

DOI: 10.1007/s12185-009-0414-2

Cite this article as:
Kasahara, I., Nishio, M., Yamamoto, S. et al. Int J Hematol (2009) 90: 413. doi:10.1007/s12185-009-0414-2

Abstract

Two multiple myeloma patients relapsed after autologous stem cell transplantation (ASCT). Conventional chemotherapy, including thalidomide, showed very little effect, but both patients responded well to a standard dose of bortezomib. One patient was treated with two additional cycles of bortezomib, but his clinical course suddenly deteriorated. Unrelated cord blood transplantation (CBT) with reduced-intensity conditioning regimen (RIC) was performed in refractory disease. After CBT, the clinical course was aggravated by tumor lysis syndrome and other conditions, thus resulting in patient death on day 34. Thereafter, we administered CBT with RIC on the second patient after just one course of bortezomib therapy since she was in partial remission. The second patient developed acute and chronic GVHD, and both responded to the steroid therapy. She has been in complete remission for more than 48 months after CBT. These results suggested that the timing of CBT with RIC may be very important, and cytoreduction with not only ASCT but also bortezomib could give a promising chance for a successful CBT.

Keywords

Cord blood transplantationAggressive myelomaBortezomib

Copyright information

© The Japanese Society of Hematology 2009